To the full analysis
Astellas Pharma stock: growth
4503.TAstellas Pharma reported $13.4B in revenue for fiscal 2026, up 11.9% on the prior year, up 11.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
4.5%
per year from 2007 to 2026, per share 5.9%
Earnings (Annual rate)
4.3%
per year from 2007 to 2026, per share 6.8%
Free cash flow (Annual rate)
8.8%
per year from 2007 to 2026, per share 10.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 11.4% | 4.5% | 4.5% |
| Revenue per share | 12.2% | 6.5% | 5.9% |
| Earnings | 19.3% | 4.2% | 4.3% |
| Earnings per share | 20.2% | 6.1% | 6.8% |
| Free cash flow | 13.0% | 6.0% | 8.8% |
| Free cash flow per share | 13.8% | 8.0% | 10.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $5.76B | $822.1M | $646.67M |
| 2008 | $6.09B | $1.11B | $999.49M |
| 2009 | $6.05B | $1.07B | $1.01B |
| 2010 | $6.1B | $765.56M | $692.6M |
| 2011 | $5.97B | $423.62M | $419.6M |
| 2012 | $6.07B | $489.87M | $782.71M |
| 2013 | $6.3B | $518.8M | $765.57M |
| 2014 | $7.14B | $569.04M | $1.18B |
| 2015 | $7.81B | $850.71M | $1.04B |
| 2016 | $8.6B | $1.21B | $1.77B |
| 2017 | $8.21B | $1.37B | $1.3B |
| 2018 | $8.14B | $1.03B | $1.81B |
| 2019 | $8.18B | $1.39B | $1.48B |
| 2020 | $8.15B | $1.22B | $1.14B |
| 2021 | $7.82B | $755.11M | $1.73B |
| 2022 | $8.12B | $777.01M | $1.42B |
| 2023 | $9.51B | $618.13M | $1.85B |
| 2024 | $10.04B | $106.73M | $897.13M |
| 2025 | $11.97B | $317.77M | $1.03B |
| 2026 | $13.4B | $1.83B | $3.18B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ¥159.70)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 2 Jan 2026)
- Valuation signal Fairly valued since 8 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.